UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Which Is Better Target Date Funds Or Age Based Strategy: Brief. A quick look at the trade-offs between these approaches to help you decide what suits you.
27,345 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
As defense budgets stabilize and technology explodes, investors are re-pricing defense names. This piece examines why...
Grayscale Investments disclosed on July 2, 2026 that its CFO for the Ethereum Staking Mini ETF is leaving after seven...
Nvidia powers the AI era, but is its stock a smart buy right now? This guide breaks down the fundamentals, compares c...
SoFi stock faces a controversial short-seller narrative. This guide explains what that means, how to evaluate the cla...
What if you could grow rental income steadily by buying on the open market and using smart loans to fuel more deals? ...
A quiet, repeating four-year rhythm has intrigued investors for decades. This article explains what the stock market ...
As regulatory debates heat up, JPMorgan’s stance on stablecoin yields could reshape how investors access digital asse...
A new nationwide survey finds just 23% of Americans correctly estimate the odds of needing long-term care in retireme...
Get ready for the genk 2025 earnings call with a clear game plan. This guide breaks down what to listen for, how to r...
QuantumScape has fallen hard in early 2026. This guide walks you through what would move the stock higher, what could...
As the S&P 500 faltered in early 2026, the Simplify Managed Futures Strategy ETF (CTA) posted gains, highlighting a h...